Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/245524
COMPARTIR / EXPORTAR:
SHARE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Koller, Dora | es_ES |
dc.date.accessioned | 2021-07-08T13:12:03Z | - |
dc.date.available | 2021-07-08T13:12:03Z | - |
dc.date.issued | 2021-06-30 | - |
dc.identifier.citation | Koller, Dora (2021) "Dataset related to Doctoral Thesis: Evaluation of genetic polymorphisms associated with the metabolic effects of aripiprazole and olanzapine [Dataset]", http://dx.doi.org/10.20350/digitalCSIC/13933 | es_ES |
dc.identifier.uri | http://hdl.handle.net/10261/245524 | - |
dc.description | File 1. Adverse events_TREATMENT The xls file shows relevant information about the treatment with aripiprazole and olanzapine, as well as about their possible adverse effects and the frequency with which they occur. File 2. Genotype Matrix. The xls file show the detected genetic polymorphism associated with the effects of aripiprazole and olanzapine | es_ES |
dc.description.abstract | Aripiprazole altered pupil contraction. Olanzapine caused significant prolactin and weight elevation. Glucose levels in glucose tolerance test were higher after olanzapine treatment. Moreover, olanzapine had more cardiovascular effects than aripiprazole. However, aripiprazole was associated to more psychiatric and nervous system adverse drug reactions. Many polymorphisms may influence pupillometric and metabolic parameters along with cardiovascular changes and adverse events. Moreover, several polymorphisms had an effect on aripiprazole, dehydro-aripiprazole and olanzapine pharmacokinetics. It seems that aripiprazole provokes less severe metabolic and cardiovascular changes, however, more adverse drug reactions were registered to it compared to olanzapine. | es_ES |
dc.description.sponsorship | European Comission ITN Treatment H2020-MSCA-ITN-721236 | es_ES |
dc.format | application/vnd.ms-excel | es_ES |
dc.language.iso | eng | es_ES |
dc.relation | info:eu-repo/grantAgreement/EC/H2020/721236 | es_ES |
dc.relation.isreferencedby | Koller, Dora. (2020). Evaluation of genetic polymorphisms associated with the metabolic effects of aripiprazole and olanzapine. http://hdl.handle.net/10486/693933. http://hdl.handle.net/10261/245523 | es_ES |
dc.rights | openAccess | en_EN |
dc.subject | Antipsychotics | es_ES |
dc.subject | Pharmagenetics | es_ES |
dc.subject | Side effects | es_ES |
dc.subject | Antipsychotics | es_ES |
dc.subject | Adverse Reactions | es_ES |
dc.title | Dataset related to Doctoral Thesis: Evaluation of genetic polymorphisms associated with the metabolic effects of aripiprazole and olanzapine | es_ES |
dc.type | dataset | es_ES |
dc.identifier.doi | 10.20350/digitalCSIC/13933 | - |
dc.description.peerreviewed | Peer reviewed | es_ES |
dc.rights.license | https://creativecommons.org/licenses/by-sa/4.0/ | es_ES |
dc.contributor.funder | European Commission | es_ES |
dc.relation.csic | No | es_ES |
oprm.item.hasRevision | no ko 0 false | * |
dc.identifier.funder | http://dx.doi.org/10.13039/501100000780 | es_ES |
dc.type.coar | http://purl.org/coar/resource_type/c_ddb1 | es_ES |
item.cerifentitytype | Products | - |
item.openairecristype | http://purl.org/coar/resource_type/c_ddb1 | - |
item.grantfulltext | open | - |
item.openairetype | dataset | - |
item.fulltext | With Fulltext | - |
item.languageiso639-1 | en | - |
Aparece en las colecciones: | (IIBM) Conjuntos de datos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Adverse events_TREATMENT-HV_v.22.xlsx | 51,58 kB | Microsoft Excel XML | Visualizar/Abrir | |
Genotype Matrix_TREATMENT_clean.xlsx | 64,02 kB | Microsoft Excel XML | Visualizar/Abrir |
CORE Recommender
Page view(s)
124
checked on 01-may-2024
Download(s)
12
checked on 01-may-2024
Google ScholarTM
Check
Altmetric
Altmetric
Este item está licenciado bajo una Licencia Creative Commons